Plain-English translation of NCT05675969 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Researchers are studying tiny fragments that cells release into the bloodstream—called microvesicles—to see if they could help diagnose pre-eclampsia, a serious pregnancy condition. This pilot study will compare the levels and types of these particles in pregnant women who have pre-eclampsia to those who do not, to understand whether these particles could be a warning sign of the disease.
Pre-eclampsia is a dangerous pregnancy complication, and doctors need better ways to detect and understand it early. Scientists believe these tiny cell fragments might be a biological marker that shows when the placenta and body are in distress—information that could help identify at-risk women sooner.
You likely qualify if…
You likely don't qualify if…
You will have two extra blood samples (about 9 mL total—roughly two teaspoons) taken during routine care at the hospital, timed as close as possible to when your condition is diagnosed. The blood is collected into special tubes and then analyzed using specialized equipment to count and identify the tiny particles. The entire process fits into your regular prenatal visits with no extra hospital trips needed.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
France
Collaborators
University of Bordeaux
Enrollment target
~20 participants
Started
May 2023
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Sex
Female only
Last updated on clinicaltrials.gov in February 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Loic Sentilhes, MD, PhD
University Hospital, Bordeaux
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.